Home Management of Simple Hydromorphone PCA Pump Mode

1. Age ≥ 18 years.

2. Patients with pathologically confirmed malignant solid tumors; patients with advanced metastatic cancer assessed by imaging

3. Patients with persistent cancer pain and an NRS score of ≥7 in the past 24 hours; or patients with refractory pain

4. Patients who have not received radiation therapy within 7 days prior to randomization and trial

5. Patients without cognitive impairment or mental illness.

6. the patient is able to complete the survey form

7. Patients can correctly understand and cooperate with the healthcare provider's medication instructions.

8. ECOG-PS ≤ 3 points.

9. Subjects voluntarily and signed the informed consent form.

10. Failure of antineoplastic treatment or refusal of antineoplastic treatment at home or community hospital.

1. Patients with a diagnosis of non-cancerous pain or pain of unknown origin.

2. Patients receiving inpatient antineoplastic therapy.

3. patients with paralytic intestinal obstruction

4. patients with opioid allergy.

5. abnormal and clinically significant laboratory results, such as creatinine ≥ 2 times the upper limit of normal, ALT or AST ≥ 2.5 times the upper limit of normal (≥ 5 times the upper limit of normal in patients with liver metastases or primary hepatocellular carcinoma), or grade C liver function Child

6. Uncontrollable nausea and vomiting.

7. Use of monoamine oxidase inhibitors within 14 days prior to randomization.

8. pregnant or lactating women; subjects with a planned pregnancy within 1 month of trial (also includes male subjects)

9. Patients with alcohol abuse.

10. Other diseases and conditions that, in the opinion of the investigator, preclude enrollment.